Analysts Have Conflicting Sentiments on These Healthcare Companies: Catalent (CTLT), Alvotech (ALVO) and Immunocore Holdings (IMCR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Catalent (CTLT – Research Report), Alvotech (ALVO – Research Report) and Immunocore Holdings (IMCR – Research Report).

Catalent (CTLT)

Barclays analyst Luke Sergott maintained a Hold rating on Catalent today and set a price target of $47.00. The company’s shares closed last Thursday at $56.96.

According to TipRanks.com, Sergott is a 1-star analyst with an average return of -3.5% and a 41.5% success rate. Sergott covers the Healthcare sector, focusing on stocks such as Fortrea Holdings Inc., Pacific Biosciences, and Twist Bioscience.

Currently, the analyst consensus on Catalent is a Hold with an average price target of $60.75.

See the top stocks recommended by analysts >>

Alvotech (ALVO)

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Alvotech, with a price target of $20.00. The company’s shares closed last Thursday at $11.67.

According to TipRanks.com, Prasad is a 3-star analyst with an average return of 2.9% and a 43.4% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Dr Reddy’s Laboratories, Pacira Pharmaceuticals, and Amneal Pharmaceuticals.

Currently, the analyst consensus on Alvotech is a Moderate Buy with an average price target of $24.00, a 105.7% upside from current levels. In a report issued on April 3, Northland Securities also maintained a Buy rating on the stock with a $28.00 price target.

Immunocore Holdings (IMCR)

Barclays analyst Peter Lawson maintained a Buy rating on Immunocore Holdings today and set a price target of $92.00. The company’s shares closed last Thursday at $62.21.

According to TipRanks.com, Lawson is a 4-star analyst with an average return of 8.3% and a 47.6% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Springworks Therapeutics, and Adaptimmune Therapeutics.

Currently, the analyst consensus on Immunocore Holdings is a Strong Buy with an average price target of $84.27.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CTLT:

• Piper Sandler healthcare/pharma analysts hold analyst/industry conference call
• William Blair healthcare analysts hold analyst/industry conference call
• A New Cause for Concern: Catalent Inc Adds a New Share Price & Shareholder Rights Risk
• Catalent to delay 10-Q filing
• Catalent price target raised to $63.50 from $56 at Baird